help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2008-0299
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colao, A.
Right arrow Articles by Lombardi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colao, A.
Right arrow Articles by Lombardi, G.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Cardiovascular Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 7 2639-2646
Copyright © 2008 by The Endocrine Society

Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy

Annamaria Colao, Rosario Pivonello, Maurizio Galderisi, Paolo Cappabianca, Renata S. Auriemma, Mariano Galdiero, Luigi M. Cavallo, Felice Esposito and Gaetano Lombardi

Department of Molecular and Clinical Endocrinology and Oncology (A.C., R.P., R.S.A., M.Galdi., G.L.), Section of Endocrinology, Department of Clinical and Experimental Medicine (M.Galde.), Section of Cardioangiology, and Department of Neurological Sciences (P.C., L.M.C., F.E.), Section of Neurosurgery, Federico II University of Naples, 80131 Naples, Italy

Address all correspondence and requests for reprints to: Annamaria Colao, M.D., Ph.D., Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University of Naples, via S. Pansini 5, 80131 Naples, Italy. E-mail: colao{at}unina.it.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Objective: The objective of the study was to investigate whether first-line surgery or somatostatin analogs (SSA) have a different outcome on cardiomyopathy after 12 months.

Design: This was a retrospective, comparative, nonrandomized study.

Patients: Fifty-six patients treated with SSA and 33 operated on by transsphenoidal approach participated in the study. For the purposes of this study, only controlled patients were included.

Measurements: Primary outcome measures were changes in left ventricular mass index, diastolic (early to atrial mitral flow velocity), and systolic performance (left ventricular ejection fraction). Secondary outcome measures were reduction of total to high-density lipoprotein-cholesterol ratio as a cardiovascular risk parameter, and improvement of glucose profile and pituitary function as indirect causes of cardiovascular improvement.

Results: SSA and surgery groups were similar for gender, age, estimated disease duration, GH and IGF-I levels, and severity of cardiomyopathy lipid and glucose profile. Twelve months after treatment in both groups, left ventricular mass index, early to atrial mitral flow velocity, diastolic blood pressure, and heart rate decreased significantly, whereas only in SSA-treated patients, left ventricular ejection fraction increased significantly. The total to high-density lipoprotein-cholesterol ratio significantly reduced only in SSA-treated patients, whereas fasting glucose levels significantly decreased only in surgery-treated patients. A normal pituitary function was found in 46.4% of SSA- and 36.4% of surgery-treated patients, with results unchanged in the former and slightly reduced in the latter.

Conclusions: Twelve months after first-line treatment with SSA or surgery, we found a similar improvement in left ventricular hypertrophy and diastolic filling. In contrast, systolic function improved more evidently in SSA-treated patients. Both a direct effect of SSA and a more preserved pituitary function might explain these results.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
Acromegaly is considered a rare disease, with an incidence of three to four cases per 1 million population per year, a prevalence of 50–80 cases per 1 million population and is caused by a GH-secreting pituitary tumor in more than 98% of cases (1). Pituitary tumors are generally benign. Nevertheless, long-standing uncontrolled GH and IGF-I excess is associated with increased mortality due to cardiovascular, cerebrovascular and respiratory diseases (2, 3, 4, 5, 6, 7). Surgery, radiotherapy, and medical therapy [dopamine agonists, somatostatin analogs (SSAs), and GH antagonists] are variably used to control hormone excess and tumor growth with different therapeutic success (8). Surgery is worldwide considered first line treatment of these pituitary tumors: disease control is achieved in most microadenomas and enclosed macroadenomas, but not in most large invasive tumors that are the majority of GH-secreting tumors (9, 10). Surgical outcome mainly depends on preoperative GH level, tumor size, invasion of surrounding structures, and experience of the surgeon (11, 12). Medical therapy with depot SSA formulations, i.e. octreotide-long-acting release (LAR) and lanreotide (LAN), is efficacious in 45–60% of unselected patients, has a good compliance, and is tolerated well by the vast majority of the patients but is costly and mostly applied as adjuvant treatment after unsuccessful surgery (1, 8, 13). SSA therapy has, however, recently been advised as first-line treatment in selected patients (14) based on rapid improvement of soft tissue swelling, i.e. reduction of macroglossia and hypertrophy of soft tissues on the first airflow tract, cardiac hypertrophy, diastolic dysfunction, arrhythmias, and sleep apnea (15), which all can complicate surgical procedures. Additionally, SSAs significantly reduce tumor mass in newly diagnosed patients (16). Indeed, a recent opinion indicates first-line treatment with SSAs in all patients with tumors larger than microadenomas and/or bearing cardiovascular or respiratory complications at diagnosis (17). Moreover, whereas several studies demonstrated a beneficial effect of SSAs on cardiovascular and respiratory complications (15), the effects of surgery have scantly been reported (18, 19, 20).

A direct comparison between the results of surgery or SSAs as first-line treatment on cardiovascular complication in acromegaly has never been performed. SSAs could have potential direct beneficial effects on the cardiovascular system as clearly demonstrated on the conduction system in which SSAs cause bradycardia and so directly improve arrhythmias (21). More recently SSAs have also been suggested to play direct effect also on cardiac performance. Smith et al. (22) have shown that somatostatin receptors (sst)-1, sst-2, sst-4, and sst-5 are coexpressed in both atrial and ventricular tissue: human cardiac myocytes expressed mRNA for only sst-1 and sst-2, whereas human cardiac fibroblasts expressed all four subtypes.

To investigate whether first-line surgery or SSAs have a different outcome on cardiomyopathy, we designed this retrospective study. Primary outcome measures were changes in left ventricular mass (LVM) and diastolic and systolic performance. Secondary outcome measures were reduction of total to high-density lipoprotein (HDL)-cholesterol ratio as a cardiovascular risk parameter and improvement of glucose profile and pituitary function as indirect causes of cardiovascular improvement.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
In 1997 we started the evaluation of the effects of the GH/IGF-I axis on the cardiovascular system. The study was approved by our ethical committee (63/97). For the purpose of this study, we reviewed all files from consecutive patients with active acromegaly coming to the Unit of Endocrinology of the Federico II University of Naples from January 1, 1997, to December 31, 2006, primarily treated with either surgery or depot SSAs, i.e. LAN or octreotide-LAR, and with an available follow-up of at least 12 months. Due to the study design, this is a nonrandomized study. However, our routine procedure generally considers first-line treatment with SSAs for 6–12 months unless the tumors are clearly noninvasive on magnetic resonance imaging and/or the patients who do not present any surgical or anesthesiological risk (17).

Inclusion criteria

Patients treated with first-line surgery via transsphenoidal route by microscopic and/or endoscopic approach or with first-line depot SSA treatment, achieving control of the disease, and with available follow-up after 12 months of treatment.

Exclusion criteria

Patients receiving second surgery within 3 months from first surgery, requiring combined dopamine agonists and SSAs because of a mixed GH/prolactin-secreting tumor, receiving the sc octreotide for longer than 15 d or requiring surgery or SSAs as second-line treatment before the completion of the 12 months or with a follow-up shorter than 6 months after surgery or pharmacotherapy.

Cure criteria

According to Giustina et al. (23), acromegaly was considered to be controlled if mean fasting GH levels were 2.5 µg/liter or less in presence of normal IGF-I levels for sex and age. Nadir GH after an oral glucose tolerance test (oGTT) of 1 µg/liter or less is also an option to evaluate disease control according with the 2000 Consensus Statement (23). However, oGTT is generally not routinely performed in patients receiving SSAs because GH-induced glucose suppression is likely to be mediated by the endogenous somatostatin tone (24). To avoid ascertainment bias, disease control after surgery and SSAs was based only on fasting GH and IGF-I levels. The diagnosis of acromegaly was defined as previously reported (1) by high serum GH levels during a 6-h time course, not suppressible less than 1 µg/l after oGTT and high plasma IGF-I levels for age [expressed as value upper limit of normal (ULN) range].

For the purpose of this study, only the patients with controlled acromegaly were included to provide a period of follow-up long enough to investigate changes in cardiomyopathy parameters.

Patients

Of 215 patients treated, 145 received first-line SSAs and 70 received surgery. Of the 145 SSA-treated patients, 32 patients were excluded because of treatment shorter than 12 months, 14 because of long-term use of sc octreotide, two were lost at follow-up, and 41 were considered noncontrolled after 6–12 months of treatment and subsequently underwent a second-line surgery. Of the 70 operated patients, 37 were excluded as not controlled and underwent a second-line SSA treatment. Therefore, in this study were included files of 89 patients (Fig. 1Go), 56 treated with SSA and 33 treated with surgery (Table 1Go). The prevalence of microadenomas and intrasellar macroadenomas (35 vs. 27, respectively) and that of extrasellar and/or invasive macroadenomas (21 vs. six, P = 0.094) was similar between the two groups.


Figure 1
View larger version (17K):
[in this window]
[in a new window]

  		FIG. 1. Flow-chart of patients enrollment into the study. OCT, Octreotide.

 

View this table:
[in this window]
[in a new window]

  		TABLE 1. Patients’ profile at diagnosis

 
Study protocol

As for our routine procedure, at diagnosis all the patients undergo a complete metabolic and endocrine screening. After an overnight fasting, serum IGF-I levels were assayed twice in a single sample at the time 0 of the GH profile; GH levels were calculated as the mean value of at least five (up to eight) samples drawn every 30 min over a period of 3–6 h, and the average value was considered for the statistical analysis; fasting total cholesterol, HDL cholesterol, glucose, and insulin levels were also measured. The total to HDL-cholesterol ratio, index of cardiovascular risk, was calculated (25). At diagnosis and 12 months after surgery or SSA (in a subset of patients as reported in Table 2Go), the oGTT was performed by measuring GH, glucose, and insulin levels every 30 min for 2 h after the oral administration of 75 g of glucose diluted in 250 ml of saline solution. Diabetes mellitus was diagnosed when fasting glucose was above 7 mmol/liter (126 mg/dl) at two consecutive measurements or when 2 h after the oGTT, glucose was 11.1 mmol/liter or greater (200 mg/dl). Impaired glucose tolerance was diagnosed when fasting glucose was less than 7 at baseline and was between 7.7 mmol/liter or greater and less than 11.1 mg/dl 2 h after the oGTT (26). Insulin resistance was estimated by the homeostasis model assessment (HOMA) score using the formula by Matthews et al. (27) [fasting serum insulin (microunits per milliliter) x fasting plasma glucose (millimoles per liter)/22.5]. The conversion factors (milligrams per deciliter to millimoles per liter) for cholesterol was 0.02586 and glucose was 0.05551. Magnetic resonance imaging of the sellar region was performed in all patients at diagnosis and 3 and 12 months after surgery or SSA.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Effect of first-line SSA therapy or surgery on GH and IGF-I levels, tumor mass and cardiovascular profile.

 
Study design

This is a retrospective, nonrandomized study to compare the outcome of first-line surgery or SSAs on acromegalic cardiomyopathy. Primary outcome measures were changes of LVM index (LVMi) as measure of left ventricular (LV) hypertrophy, early to atrial mitral flow velocity (E/A) as measure of diastolic function, and LV ejection fraction (LVEF) as measure of systolic function. Secondary outcome measures were changes in the total to HDL cholesterol ratio; glucose tolerance, measured as fasting glucose levels and HOMA reduction; and improvement of pituitary function.

In this study we included the results recorded at diagnosis and 12 months after either surgery of SSA treatment. In the SSA-treated patients, GH and IGF-I levels and lipid and glucose profile were collected the day before the next drug injection.

Diagnosis of hypopituitarism (28)

Gonadotropin deficiency was established on the basis of low testosterone levels (<3 µg/liter) in men or low 17 β-estradiol levels (<50 ng/liter) in premenopausal women and on low FSH and LH levels (<2 UI/liter) in postmenopausal women; TSH deficiency was established on the basis of low TSH levels (<0.5 mIU/liter) in presence of free T3 and free T4 levels below or in the lower part of the normal range; ACTH deficiency was established on the basis of low morning cortisol levels (<50 µg/liter) or less than 200 µg/liter after administration of 250 µg im synacthen. None of our patients had diabetes insipidus.

Treatment protocol

To investigate individual patient’s tolerability, before starting SSA, all patients received an acute test with octreotide at a dose of 0.1 mg in the morning after an overnight fast and at least 2 h of bed rest (29). Of the 56 patients, 42 were treated with octreotide-LAR (10–40 mg every 28 d) and 14 with LAN (30–120 mg every 28 d). The dosages were up-titrated to control GH and IGF-I levels, which was obtained in all patients.

Echocardiography

Echocardiography by M-mode, two-dimensional, and pulsed Doppler-derived mitral inflow during three to five consecutive cardiac cycles, according to the recommendations of the American Society of Echocardiography (30). The following measurements were determined on M-mode tracing: interventricular septum thickness, LV internal end-diastolic diameter (LVID) and posterior wall thickness, LVM calculation by the Devereux’s formula (31): LVM = 1.04 [(interventricular septum thickness +LVID+ posterior wall thickness)3 – (LVID)3] – 14 g. An LVMi of 135 g/m2 or greater in men and 110 g/m2 or greater in women was considered as cutoff points for left ventricular hypertrophy. Diastolic function was evaluated by pulsed Doppler mitral inflow as E/A ratio, indicating the normal pattern of ventricular diastolic filling at 1 or greater. Left ventricular systolic function was evaluated by ejection fraction (LVEF) normal when greater than 50%. Structural alterations in the cusps and annuluses of the heart valves were diagnosed by thickened and bright echoes on both M-mode and cross-sectional echocardiogram, using established diagnostic criteria (32). The diagnosis of valve stenosis or valve prolapse was made on the basis of morphologic assessment and Doppler echocardiography. Significant regurgitation was defined as a regurgitant jet on the color and pulsed Doppler echocardiogram extending more than 2 cm behind the plane of the aortic or mitral valve and pandiastolic (aortic regurgitation) or pansystolic (mitral regurgitation) regurgitant flow of more than 2 m/sec on continuous-wave Doppler. Regurgitation was classified as mild, moderate, or severe on the basis of the extent to which retrograde flow filled the atrium or the ventricle (less than one third, to two thirds, or more than two thirds).

Assays

GH levels were assayed by immunoradiometric assays. The sensitivity of the assay was 0.2 µg/liter until 2002 or 0.05 µg/liter thereafter. The intra- and interassay coefficients of variation (CVs) were, respectively, 4.5 and 7.9%. Serum IGF-I was measured by immunoradiometric assay after ethanol extraction (Diagnostic System Laboratories Inc., Webster, TX). The normal ranges in 20 or less, 21–30, 31–40, 41–50, 51–60, 61–70, and older than 70-yr-old men were 180–625, 118–475, 102–400, 100–306, 95–270, 88–250, and 78–200 µg/liter, respectively, whereas in women they were 151–530, 118–450, 100–390, 96–288, 90–250, 82–200, and 68–188 µg/liter, respectively. The sensitivity of the assay was 0.8 µg/liter. The intraassay CVs were 3.4, 3.0, and 1.5% for low, medium, and high points of the standard curve, respectively. The interassay CVs were 8.2, 1.5, and 3.7% for low, medium, and high points of the standard curve. Data are shown as ULN (normal = ≤ 1).

Statistical analysis

Results were expressed as mean ± SD unless otherwise specified. The statistical analysis was performed by MedCalc Software for Windows (MedCalc, Mariakerke, Belgium) package using nonparametric tests. The comparison between surgery- and SSA-treated patients (at study entry and end) was performed by the Mann-Whitney U test. The comparison between baseline and 12 months after treatment results in the surgery- and SSA-treated patients was performed by the Wilcoxon signed rank test. The significance was set at 5% and is reported as two-sided P values. For categorical variables, differences were analyzed by the {chi}2 test and Fisher’s exact test. Correlation test was used to evaluate whether percent GH and IGF-I suppression after surgery or SSAs were correlated with percent changes of LVMi, E/A, or LVEF: for this purpose the Spearman’s rho with the 95% confidence interval was calculated.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Baseline characteristics (Table 1Go)

First-line treatment with SSAs or surgery groups were similar for gender, age, estimated disease duration, GH, and IGF-I levels. Only the tumor volume was significantly smaller in surgically treated than in SSA-treated patients. The severity of cardiomyopathy was also similar as well as impairment of lipid and glucose profile and insulin resistance index (Table 2Go). Structural alterations of the mitral and aortic valves (fibrosis, fibrosclerosis, or thickening of the annulus or leaflets) were found in 38 and 42 of SSA-treated patients and 22 (P = 0.91) and 19 (P = 0.14) patients treated with surgery, respectively. None of the patients had mitral prolapse; eight of SSA patients and none of surgery patients had aortic ectasia (P = 0.058).

According with inclusion criteria, all patients normalized GH and IGF-I levels. As expected the posttreatment tumor volume was significantly greater in SSA-treated than surgery-treated patients (Table 2Go). Percent tumor shrinkage in this series was by 56.9 ± 23.3% after SSA and 99.9 ± 0.2% after surgery (P < 0.0001).

Primary end point: SSA therapy vs. surgery on cardiomyopathy (Table 2Go)

In both groups, LVMi, E/A, diastolic blood pressure, and heart rate decreased significantly, whereas only in SSA-treated patients, LVEF increased significantly. After 12 months of treatment, E/A was significantly higher and heart rate was significantly lower in the SSA-treated than the surgery-treated patients. Percent changes in LVMi, E/A, and LVEF were significantly lower and higher, respectively, in SSA-treated than the surgery-treated patients (Fig. 2Go). Decrease of diastolic blood pressure but not of systolic blood pressure was observed in both groups; heart rate was significantly lower after 12 months in SSA-treated than surgery-treated patients (Table 2Go). The prevalence of LV hypertrophy and diastolic and systolic dysfunction was significantly reduced only in the SSA-treated cohort (Table 3Go). In contrast, the prevalence of arrhythmias and hypertension did not significantly change in both cohorts (Table 3Go). Only a minority of patients had mitral or aortic regurgitation (mild in all cases): no change was observed after either SSA or surgery (Table 3Go). Treatment with angiotensin-convertase inhibitors was performed in 11 SSA-treated patients (19.6%) and seven of those surgery treated (12.5%, P = 0.96) and β-blockers in one patient in both groups.


Figure 2
View larger version (15K):
[in this window]
[in a new window]

  		FIG. 2. Percent changes of LVMi, E/A ratio, and LVEF.

 

View this table:
[in this window]
[in a new window]

  		TABLE 3. Effect of primary SSA therapy or surgery on cardiomyopathy and cardiovascular morbidity

 
Neither GH nor IGF-I percent suppression was correlated with percent changes of LVMi, E/A, or LVEF after SSA or surgery (data not shown).

Secondary end point: SSA therapy vs. surgery on lipid and glucose profile and residual pituitary function

The total to HDL-cholesterol ratio significantly decreased only in SSA-treated patients, whereas fasting glucose levels significantly decreased only in surgery-treated patients (Table 2Go). However, because of a significant reduction of insulin levels, the HOMA index significantly decreased in both groups. Glucose abnormalities, however, did not significantly change in both groups (Table 3Go).

At diagnosis a normal pituitary function was found in 20 of 56 SSA-treated patients (35.7%) and 21 of 33 surgery-treated patients (63.6%; P = 0.020), deficit in one axis in 26.8 and 18.2% patients (P = 0.51) and two axes or more in 37.5 and 18.2% patients (P = 0.094) (Table 4Go). After treatment, a normal pituitary function was found in 46.4 and in 36.4%, in SSA- and surgery-treated patients, resulting in no change in the former and slightly reduced in the latter (Table 4Go). In SSA-treated patients, the prevalence of two deficits reduced significantly after 12 months, whereas no difference was noted in the surgery group (Table 4Go). In SSA-treated patients, improvement was observed in FSH and LH axes; reduced TSH levels in the absence of changes in thyroid hormone levels was also noted. In the surgery group, four patients improved their pituitary function (12.1%), 15 remained stable (45.5%), whereas 14 (42.4%) acquired one (eight of 14), two (five of 14), or three deficits (one of 14 patients). Replacement therapy was, however, started in only five men requiring testosterone and another three women requiring T4 (eight of 14; 57.1%); gonadotropins deficiency was not replaced in five postmenopausal women and another two men aged above 70 yr because testosterone levels were in the lower normal range (2.9–3.2 µg/liter).


View this table:
[in this window]
[in a new window]

  		TABLE 4. Effect of primary SSA therapy or surgery on cardiomyopathy

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
This is the first study comparing the outcome of first-line SSA or surgery in patients with controlled acromegaly in relation of cardiovascular morbidity.

In recent years, the issue of first-line therapy of acromegaly has been highly debated based on the following concepts: 1) surgery is successful in microadenomas and enclosed macroadenomas of limited efficacy in large adenomas, which represent the majority of GH-secreting pituitary tumors (8, 17, 33), and it is rather safe but not devoid of potential complications (34, 35) and should be performed only in experienced centers having one neurosurgeon specialized in the treatment of pituitary tumors (11, 12) to ensure an optimal outcome and safety; and 2) depot somatostatin analogs are effective in controlling acromegaly in about 50% of patients in different series, and results are less dependent on tumor size (8, 13, 14, 17, 33, 36), improve clinical signs and symptoms, even when IGF-I levels are not normalized (13), and reduce cardiovascular morbidity and sleep apnea (15) so reducing the anesthetic risk (37), and inducing tumor shrinkage (14, 16). First-line SSA therapy is, however, still suggested only in selected patients with high perioperative morbidity or in those who refuse surgery (8). Therefore, SSA therapy is generally used as adjuvant treatment after unsuccessful surgery. Major drawbacks of lifelong primary treatment with SSA are the high costs of the drugs, the requirement of lifelong treatment that limits compliance, and the prevalence of side effects. In general, side effects do not limit therapy, but a number of studies reported 3–5% dropout rates, in one study up to 25% (13).

Of the still unknown information related to the efficacy of treatment of acromegaly is the effect on cardiovascular morbidity. It is well known that longstanding GH and IGF-I excess in acromegaly causes a specific cardiomyopathy that characteristically has biventricular hypertrophy, reduced diastolic filling, and, more rarely, reduced systolic performance (15). Suppression of GH and IGF-I has been widely reported to improve the acromegalic cardiomyopathy (15). However, the vast majority of data concern treatment with SSA, and only a few are related to postsurgery cardiovascular morbidity (15). Very recently De Marinis et al. (20) reported a similar efficacy of surgery and SSA in a small series of patients followed for 12 months after successful treatment of acromegaly. They confirmed that a reduction in the LV hypertrophy with an improvement in diastolic function in both patients with controlled disease and those with poorly controlled disease undergoing SSA treatment (20). Apparently they did not find any difference in echocardiographic parameters between SSA and surgery (20). The series of patients was, however, small, and the patients treated with SSA received previous unsuccessful surgery so that the analysis of SSA treatment was biased, and no information was available for cardiovascular risk parameters, glucose profile, and pituitary deficiencies.

In 1990 we begun a systematic evaluation of cardiac morphology and function by echocardiography and common cardiovascular risk factors (lipid profile, fibrinogen levels, and insulin resistance) to investigate the effect of different therapies on the acromegalic cardiomyopathy. This database has subsequently been approved by our institutional Ethical Committee in 1997.

The results of this study, even with the limitation of being retrospective and nonrandomized, demonstrate that successful treatment with acromegaly is followed by a significant improvement of several aspects of cardiovascular morbidity, mainly left ventricular hypertrophy and, likely consequently, diastolic filling. However, disease control achieved with surgery or SSA is also followed by some different cardiovascular results. We have already reported that SSAs have a remarkable effect on heart rate and arrhythmias (38): even if the difference was not statistically significant, none of the six patients with arrhythmias before starting SSA required a specific treatment, compared with the only patient cured by surgery. More importantly, systolic function improved significantly only in SSA-treated patients. We previously reported that insufficiency systolic function at rest, as measured by echocardiography, is not frequent in acromegaly, whereas its response on effort is impaired in most patients, even in the young (15). Indeed, in this cohort, a value of ejection fraction, the parameter we used as a surrogate of systolic function, resulted to be lower than 50% (the normal threshold value) in 25% of the SSA cohort and 21.2% of the surgery cohort, even if in the former, the residual pituitary function was more frequently impaired. We observed an increase in the mean ejection fraction values 12 months after SSA, whereas they remained stable in the surgery group: consequently systolic function normalized more frequently in the SSA- than the surgery-treated patients. Whether this result is obtained because of direct effects of SSA on cardiomyocytes as recently suggested (22) or is indirectly caused by subtle changes in the remaining pituitary function cannot be ruled out from these data. As for cardiac valve disease, we previously demonstrated that apparently no difference in the prevalence of cardiac valve disease after treatment of acromegaly (39) as also confirmed by van der Klaauw et al. (40). In this study, we also confirm that no significant change occurs in cardiac valve disease after 12 months of SSA or surgery.

It is, however, of interest that the two different approaches have differential effects on lipids and glucose profile that indirectly relate with cardiovascular risk. It is known that glucose tolerance is better after surgery than after SSA (41), even if we did not find any significant dose-dependent detrimental effects of octreotide-LAR on glucose tolerance, even at high doses (42). It is well accepted, anyway, that suppression of insulin levels might impair glucose tolerance in individual patients, but generally this phenomenon is short lasting and is overcome by the beneficial effect on glucose tolerance of suppressed GH levels.

Data comparing lipid profile after SSA or surgery are lacking, and overall data on lipid profile are rather conflicting (15). Whether the differential effect we found in reducing the total to HDL cholesterol ratio depends also on different pituitary function posttreatment remains to be determined.

The issue of the preservation of pituitary function after SSA and surgery has been very scantly reported. In general surgery is considered safe and beneficial for pituitary function. In fact, we did not find any difference in the prevalence of one, two, or three pituitary deficits in SSA- or surgery-treated patients. The prevalence of intact pituitary function decreased significantly after surgery, even if the effect was minor and mainly played on gonadotropins levels, but this patient cohort started with a more frequent normal pituitary function before treatment.

Conclusion

In this retrospective study, 12 months after first-line treatment with SSA or surgery, we found a significant improvement in left ventricular hypertrophy and diastolic filling. In contrast, systolic function improved more evidently in SSA-treated patients. Whether this is a direct effect of SSAs or is mediated by a more preserved pituitary function cannot be ruled out from the current study. Importantly, arrhythmias disappeared in all SSA-treated patients. Because our results derive from a nonrandomized study, they suggest that cardiovascular morbidity after first-line treatment of acromegaly should be investigated in detail to more carefully investigate the consequences that SSAs or surgery has on the cardiovascular system, the most important cause of death in this disease (2, 3, 4, 5, 6, 7).


   Footnotes
 
The paper has been registered by A.C. in the www.clinicaltrials.gov database with the ID NCT00615004.

Disclosure Statement: None of the authors have conflict of interest to disclose.

First Published Online April 29, 2008

Abbreviations: CV, Coefficient of variation; E/A, early to atrial mitral flow velocity; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LAN, lanreotide; LAR, long-acting release; LV, left ventricular; LVEF, LV ejection fraction; LVID, LV internal end-diastolic diameter; LVM, LV mass; LVMi, LVM index; oGTT, oral glucose tolerance test; SSA, somatostatin analog; sst, somatostatin receptor; ULN, upper limit of normal.

Received February 8, 2008.

Accepted April 17, 2008.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Colao A, Lombardi G 1998 Growth hormone and prolactin excess. Lancet 352:1455–1461[CrossRef][Medline]
  2. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE, the United Kingdom Acromegaly Study Group 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 83:2730–2734[Abstract/Free Full Text]
  3. Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419–3426[Abstract/Free Full Text]
  4. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86–91[CrossRef][Medline]
  5. Holdaway IM, Rajasoorya CR, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674[Abstract/Free Full Text]
  6. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613–1617[Abstract/Free Full Text]
  7. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081–4086[Abstract/Free Full Text]
  8. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058[Free Full Text]
  9. Kreutzer J, Vance ML, Lopes MB, Laws Jr ER 2001 Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072–4027[Abstract/Free Full Text]
  10. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA 1996 Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45:407–413[CrossRef][Medline]
  11. Ahmed S, Elsheikh M, Page RCL, Adams CBT, Wass JAH 1999 Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 50:561–567[CrossRef][Medline]
  12. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM 1998 The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas. Clin Endocrinol (Oxf.) 49:653–657
  13. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013–3018[Free Full Text]
  14. Sheppard MC 2003 Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387–399[CrossRef][Medline]
  15. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102–152[Abstract/Free Full Text]
  16. Bevan JS 2005 The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856–1863[Abstract/Free Full Text]
  17. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, and the participants of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group 2006. J Endocrinol Invest 29:1017–1020
  18. Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C, Cantore G, Tamburrano G, Cassone R 2001 Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 55:307–313[CrossRef][Medline]
  19. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 86:1551–1557[Abstract/Free Full Text]
  20. De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A 2007 The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11:13–20[CrossRef]
  21. Herrington AM, George KW, Moulds CC 1998 Octreotide-induced bradycardia. Pharmacotherapy 18:413–416[Medline]
  22. Smith WH, Nair RU, Adamson D, Kearney MT, Ball SG, Balmforth AJ 2005 Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol 187:379–386[Abstract/Free Full Text]
  23. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529[Abstract/Free Full Text]
  24. Shibasaki T, Masuda A, Hotta M, Yamauchi N, Hizuka N, Takano K, Demura H, Shizume K 1989 Effects of ingestion of glucose on GH and TSH secretion: evidence for stimulation of somatostatin release from the hypothalamus by acute hyperglycemia in normal man and its impairment in acromegalic patients. Life Sci 44:431–418[CrossRef][Medline]
  25. Castelli WP 1996 Lipid, risk factors and ischaemic heart disease. Atherosclerosis 124:(Suppl):S1–S9
  26. World Health Organization 1999 Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization
  27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419[CrossRef][Medline]
  28. Lamberts SW, de Herder WW, van der Lely AJ 1998 Pituitary insufficiency. Lancet 352:127–134[Medline]
  29. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356–2362[Abstract]
  30. Sahn DJ, De Maria A, Kissio J, Weyman A 1978 The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiography measurements. Circulation 58:1072–1083[Abstract/Free Full Text]
  31. Devereux RB 1987 Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 9(Suppl 2):19–26
  32. Feigenbaum H 1994 Echocardiography. 5th ed. Philadelphia: Lea and Febiger
  33. Melmed S 2006 Acromegaly. N Engl J Med 355:2558–2573[Free Full Text]
  34. Ciric I, Ragin A, Baumgartner C, Pierce D 1997 Complications of transsphenoidal surgery: results of a National survey, review of the literature and personal experience. Neurosurgery 40:225–237[CrossRef][Medline]
  35. Cappabianca P, Cavallo LM, Colao A, de Divitiis E 2002 Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg 97:293–298[Medline]
  36. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465–4473[Abstract/Free Full Text]
  37. Ben-Shlomo A, Melmed S 2003 The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 88:963–968[Free Full Text]
  38. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S, the Multicenter Italian Study Group on Lanreotide 2003 Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced growth hormone and insulin-like growth factor-I decrease in acromegaly: a single-blind prospective multicenter study. J Endocrinol Invest 25:971–976
  39. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G 2003 High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88:3196–3201[Abstract/Free Full Text]
  40. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, van der Wall EE, Smit JW, Romijn JA, Pereira AM 2006 Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 16:101–107[CrossRef][Medline]
  41. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M 2006 Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128[Abstract/Free Full Text]
  42. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G 2007 Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157:579–587[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, R. S. Auriemma, M. Galdiero, P. Cappabianca, L. M. Cavallo, F. Esposito, L. F. S. Grasso, G. Lombardi, and R. Pivonello
Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study
J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 528 - 537.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colao, A.
Right arrow Articles by Lombardi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colao, A.
Right arrow Articles by Lombardi, G.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Cardiovascular Endocrinology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals